227. オスラー病 Osler disease Clinical trials / Disease details

臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

diseases per page:

Showing 1 to 10 of 56 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03850730 (ClinicalTrials.gov)	July 1, 2023	12/2/2019	Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia	An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in H ...	Hereditary Hemorrhagic Telangiectasia;Epistaxis	Drug: Pazopanib	Cure HHT	University of North Carolina	Not yet recruiting	18 Years	75 Years	All	30	Phase 1/Phase 2	NULL
2	NCT05632484 (ClinicalTrials.gov)	December 1, 2022	21/10/2022	Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, i ...	Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, i ...	Hereditary Haemorrhagic Telangiectasia	Biological: Cord blood sampling;Biological: Cord sampling	Hospices Civils de Lyon	NULL	Not yet recruiting	N/A	N/A	All	16	N/A	France
3	NCT03850964 (ClinicalTrials.gov)	December 1, 2022	12/2/2019	Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)	A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of up to 2 ...	Hereditary Hemorrhagic Telangiectasia;Epistaxis;Anemia;Nosebleed;HHT	Drug: Pazopanib;Drug: Placebo oral capsule	Cure HHT	United States Department of Defense	Not yet recruiting	18 Years	80 Years	All	70	Phase 2/Phase 3	NULL
4	NCT05406362 (ClinicalTrials.gov)	July 18, 2022	10/5/2022	Assess Safety and Efficacy of VAD044 in HHT Patients	A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Saf ...	Hereditary Hemorrhagic Telangiectasia (HHT)	Drug: VAD044	Vaderis Therapeutics AG	NULL	Recruiting	18 Years	N/A	All	80	Phase 1	United States;Canada;Italy;Netherlands;Spain
5	EUCTR2018-004179-11-IT (EUCTR)	03/09/2021	17/08/2021	Effectiveness of somatostatin analogues for GI bleeding in patients with hereditaryhemorrhagic telan ...	Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagictelangiectasia and sy ...	Hereditary hemorrhagic telangiectasia(HHT), also known as Osler–Weber–Rendu disease(in specific pati ...	Product Name: octreotide a azione pronta 0,1 mg Product Code: [OCTREOTIDE ACETATO] INN or Proposed INN: ...	RADBOUD UNIVERSITY MEDICAL CENTER	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Denmark;Netherlands;Germany;United Kingdom;Italy
6	ChiCTR2100043253	2021-02-17	2021-02-09	The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab i ...	The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab i ...	hereditary hemorrhagic telangiectasia	Trial group:Bevacizumab;	Shandong Provincial ENT Hospital	NULL	Recruiting	16	75	Both	Trial group:30;	Phase 4	China
7	EUCTR2018-004179-11-FR (EUCTR)	20/01/2021	26/11/2020	The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber di ...	Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasiaand sy ...	Hereditary hemorrhagic telangiectasia(HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: Octreotide INN or Proposed INN: OCTREOTIDE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Germany;Netherlands
8	NCT04404881 (ClinicalTrials.gov)	November 23, 2020	22/5/2020	Bevacizumab In Hereditary Hemorrhagic Telangiectasia	A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrh ...	Hereditary Hemorrhagic Telangiectasia	Drug: Bevacizumab	Hanny Al-Samkari, MD	NULL	Recruiting	18 Years	N/A	All	20	Phase 2	United States
9	NCT04646356 (ClinicalTrials.gov)	October 20, 2020	20/10/2020	Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)	Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)	Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed	Drug: Tacrolimus capsule (low-dose)	Unity Health Toronto	United States Department of Defense	Recruiting	18 Years	N/A	All	30	Phase 2	Canada
10	EUCTR2018-004179-11-DE (EUCTR)	12/08/2020	12/03/2020	The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber di ...	Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and sy ...	Hereditary hemorrhagic telangiectasia(HHT), also known as Osler–Weber–Rendu disease (in specific pat ...	Other descriptive name: OCTREOTIDE ACETATE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Netherlands;Germany;United Kingdom;Italy

First Previous1 2 3 4 5 6Next Last